Chemotherapy-induced diarrhoea (CID) is a risk of antineoplastic regimens, often associated with 5-fluorouracil (5-FU), irinotecan and capecitabine. Current treatment guidelines for CID include the use of loperamide and octreotide but do not account for other therapies, including budesonide. Small case reports have shown benefit with budesonide in CID secondary to 5-FU and irinotecan, but there is no literature base addressing budesonide use in CID secondary to capecitabine. We describe a case of a patient with severe capecitabine-induced diarrhoea that was refractory to guideline based therapy but resolved with the use of budesonide.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887426 | PMC |
| http://dx.doi.org/10.1136/bcr-2019-231544 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Usefulness of Hospital and Community Pharmacists Collaborating to Manage Capecitabine-induced Severe Hand-foot Syndrome in Patients with Breast Cancer.
Asian Pac J Cancer Prev
November 2024
Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Background: The management of capecitabine-related hand-foot syndrome (HFS) is critical to avoid progression of the syndrome through early detection and early response; management of HFS involves joint medication management by physicians and pharmacists (hospital and community pharmacists). This study aimed to evaluate the effectiveness of collaborative medication management in cancer patients with HFS by comparing its effectiveness with the traditional response using monitoring reports from community pharmacists.
Patients And Methods: Medical records of 120 breast cancer patients who received capecitabine therapy between September 2017 and August 2023 were retrospectively reviewed.
The Descriptive and Disproportionality Assessment of EudraVigilance Database Reports on Capecitabine Induced Cardiotoxicity.
Cancers (Basel)
November 2024
Preclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.
Unlabelled: Capecitabine (CAP) is one of the most commonly prescribed fluoropyrimidines in oncology, especially in the treatment of colon cancer. Cardiac toxicity is a severe and potentially lethal adverse drug reaction (ADR) against fluoropyrimidines. Cardiac ADRs, such as myocardial infarction (MI), heart failure (HF), arrhythmias, and a number of cardiomyopathies, are reported for these molecules.
View Article and Find Full Text PDFManagement of severe capecitabine-induced corneal toxicity.
Am J Ophthalmol Case Rep
December 2024
Dept of Ophthalmology, Ghent University Hospital, Belgium.
Purpose: To describe the clinical presentation and management of severe capecitabine-induced corneal toxicity.
Observations: A 71-year-old woman presented with severe bilateral vision loss. Four months earlier, capecitabine was initiated for a metastatic invasive ductal carcinoma.
Capecitabine-Induced Genital Hand-Foot Syndrome Treated With Topical Tacrolimus.
Cureus
April 2024
Oncology, Huntington Hospital, Los Angeles, USA.
We describe a rare case of capecitabine-induced palmar-plantar erythrodysesthesia (PPE), or hand-foot syndrome (HFS), involving the genitals, which resolved with tacrolimus therapy, in a patient with cT3dN3 stage IIIc moderately differentiated proximal rectal adenocarcinoma who was undergoing neoadjuvant chemotherapy. Given its severe impact on the quality of life, HFS often requires independent local anti-inflammatory treatment and subsequent dose delay and/or modification of the patient's chemotherapy. We believe that our findings in this report can aid clinicians in the early recognition and management of capecitabine-associated HFS resulting in balanitis, as prompt treatment may reduce morbidity and avoid prolonged interruption of chemotherapy in these patients.
View Article and Find Full Text PDFCapecitabine-induced severe adverse events-therapeutic drug monitoring and -gene analysis are recommended.
BMJ Case Rep
April 2024
Department of Visceral Surgery, Clarunis University Digestive Health Care Center Basel, Basel, Switzerland.
In this report, two cases of patients with severe adverse events after an adjuvant treatment with capecitabine are described in detail. The first patient suffered from a severe ileocolitis, where ultimately intensive care treatment, total colectomy and ileum resection was necessary. The second patient experienced a toxic enteritis, which could be managed conservatively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!